Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. · 2019
Read Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. by Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6441150.txt.
Introduction
Yi and co-authors review the case for pairing immune checkpoint blockade with anti-angiogenesis drugs in cancer treatment. Checkpoint inhibitors free T cells to attack tumors, but response rates stay low and resistance is common. Blocking blood-vessel growth does more than starve a tumor; it also reshapes the immune environment around it.
In animal studies the combination beat either therapy alone, raising the share of anti-tumor immune cells and cutting expression of several checkpoints besides PD-1. Clinical trials built on those results were reporting promising outcomes as the review was written. Biomarkers such as PD-L1 and lymphocyte infiltration still guide patient selection, and the pairing offers one route past monotherapy resistance.
Catalog record
| CREATOR | Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment By Ming Yi, Dechao Jiao, Shuang Qin, Qian Chu, Kongming Wu, Anping Li Published in: Molecular Cancer DOI: 10.1186/s12943-019-0974-6 ABSTRACT Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for choosing ICI is the low response rate. Even though multiple predictive biomarkers such as PD-L1 expression, mismatch-repair deficiency, and status of tumor infiltrating lymphocytes have been adopted for patient selection, frequent resistance to ICI monotherapy has not been completely resolved. However, some recent studies indicated that ICI resistance could be alleviated by combination therapy with anti-angiogenesis treatment. Actually, anti-angiogenesis therapy not only prunes blood vessel which is essential to cancer growth and metastasis, but also reprograms the tumor immune microenvironment. Preclinical studies demonstrated that the efficacy of combination therapy of ICI and anti-angiogenesis was superior to monotherapy. In mice model, combination therapy could effectively increase the ratio of anti-tumor/pro-tumor immune cell and decrease the expression of multiple immune checkpoints more than PD-1. Based on exciting results from preclinical studies, many clinical trials were deployed to investigate the synergistic effect of the combination therapy and acquired promising outcome. This review summarized the latest understanding of ICI combined anti-angiogenesis therapy and highlighted the advances of relevant clinical trials. BACKGROUND Immune checkpoint molecules mainly includes programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) [1–4]. As the vital components of immune homeostasis, immune checkpoint molecules downregulate magnitude of immune response and participate in peripheral tolerance [5]. However, upregulated immune checkpoint signaling pathways such as PD-1/PD-L1 protect cancer cell from immune surveillance [6]. Therefore, immune checkpoint molecules and their ligands are ideal anti-cancer treatment targets. It is well established that anti-PD-1/PD-L1 upregulates Ras-Raf-MEK-ERK and PI3K-AKT signaling pathways in immune cells by blocking PD-1/PD-L1 axis [7]. As a result, anti-PD-1/PD-L1 therapy restores T cell from exhausted status and enhances tumor-killing activity [8]. Relatively, mechanisms by which anti-CTLA-4 therapy destroys cancer cell are still controversial. It is generally believed that anti-CTLA-4 recovers the co-stimulatory signaling pathway CD28-B7 which is usually hijacked by CTLA-4 in tumor microenvironment [9, 10]. Additionally, it is proposed that anti-CTLA-4 could directly eliminate regulatory T (Treg) cell by antibody-dependent cell-mediated cytotoxicity [11–13]. Compared with immune checkpoint inhibitor (ICI), anti-angiogenesis therapy attracted intensive attention earlier. Angiogenesis, mainly indicating the generation of new vessels from pre-existing ones, occurs in many physiological processes (e.g. wound healing) [14]. In the meanwhile, angiogenesis participates in the growth and metastasis of solid tumor [15]. Due to the characteristics of the rapid division and growth, tumor cell consumes a large amount of oxygen and nutrients. Besides, active metabolism with disproportional blood supply leads to hypoxia and acidosis in tumor bed [15, 16]. Subsequently, hypoxia induces tumor and stroma cells to secret multiple pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinase (MMP) [17]. As a result, the local balance of pro-angiogenic factors and anti-angiogenic factors is disturbed and multiple angiogenic pathways are activated [18]. However, due to the persistent hypersecretion of pro-angiogenic factors in tumor microenvironment, vessel maturation process is impeded [19]. Abnormal angiogenesis leads to the lack of pericyte coverage and leaky nascent vessels [20, 21]. Disorganized and leaky vessels result in increased vascular permeability and interstitial fluid pressure [22]. The initial aim of anti-angiogenesis therapy is to reduce blood supply and starve tumor cell of oxygen and nutrients [23]. However, no significant improvements in outcomes were observed in patients undergoing anti-angiogenesis therapy alone. Vessel normalization theory provides a novel perspective in anti-angiogenesis and indicates potential synergistic effect in combination with other therapies. This review focused on the application of ICI combined with anti-angiogenesis therapy. THE INFLUENCE OF ANGIOGENESIS ON ICI THERAPY The status of tumor infiltrating lymphocytes determines the efficacy of ICI Tumor infiltrating lymphocyte (TIL) is one of the most important components for tumor-killing activity. For ICI therapy especially anti-PD-1/PD-L1 intervention, pre-existing TIL is the necessary precondition for potent tumor regression. Based on the status of pre-existing TIL, tumor microenvironments are classified into three types: (I) immune inflamed type, where dense functional CD8+ T cells infiltrate; (II) excluded infiltration type, where abnormal angiogenesis and immunosuppressive reactive stroma prevent the infiltration of T cell; (III) immune ignorance type, where tumor mutation burden and the expression of antigen presentation machinery marker are low [24]. It was verified that the tumors belonging to immune inflamed type were more sensitive to ICI therapy than two other types [25]. Moreover, treatment enhancing T cell infiltration could promote the effect of ICI [26, 27]. Angiogenesis affects the status of TIL In cancer-immunity cycle, the presentation of neoantigen determines the generation of tumor specific T cell clones. Then, T cells with specific T cell receptor (TCR) traffic to and infiltrate into tumor. TIL recognizes neoantigen and kills tumor cell in immunosupportive tumor microenvironment [28, 29]. For most growing solid tumors, hyperactive angiogenesis contributes to immunosuppressive microenvironment by affecting multiple immune steps (Fig. 1) [30, 31].Fig. 1Tumor angiogenesis induces the formation of immunosuppressive tumor microenvironment. Firstly, leaky nascent vessels and loose pericyte coverage result in high interstitial fluid pressure (IFP) which means greater pressure difference to overcome for T cell infiltration. Secondly, neo-vasculatures tend to lack some adhesion molecules for example vasculature cell adhesion molecule-1 (VCAM-1). Thirdly, hypoxia upregulates some inhibitory signals for anti-tumor immune response such as PD-L1, indoleamine 2, 3-dioxygenase (IDO), interleukin-6 (IL-6), and interleukin-10 (IL-10) . In addition, circulating VEGF impedes the maturation and function of dendritic cell (DC). Besides, tumor hypoxia induces upregulation of chemokine (C-C motif) ligand-22 and chemokine (C-C motif) ligand-28, which recruit Treg into tumor [36, 37]. Moreover, hypoxic tumor microenvironment promotes the polarization of tumor-associated macrophage (TAM) to M2-like phenotype. Lastly, the expression of Fas ligand (FasL) on tumor endothelial barrier selectively eliminates effector CD8+ T cells rather than Treg, due to the high expression of cellular FLICE-inhibitory protein (c-FLIP) expression on Treg. In summary, angiogenesis render accumulating pro-tumor immune cells and decreasing anti-tumor immune cells, inducing the formation of immunosuppressive tumor microenvironment On the one hand, abnormal angiogenesis decreases the abundance and function of anti-tumor lymphocytes. Firstly, leaky nascent vessels and loose pericyte coverage result in high interstitial fluid pressure which means greater pressure difference to overcome for T cell infiltration. Rare T cell could cross physical barrier and infiltrates into tumor bed [32]. Secondly, neo-vasculatures tend to lack some adhesion molecules for example vasculature cell adhesion molecule-1 (VCAM-1). Downregulated adhesion molecules further impair the extravasation of T cell [32]. Thirdly, neo-vasculatures could not compensate for increased oxygen consumption and concurrent hypoxia directly undermine the functions of TIL. Hypoxia upregulates some inhibitory signals for anti-tumor immune response such as PD-L1, indoleamine 2, 3-dioxygenase (IDO), interleukin-6 (IL-6), and interleukin-10 (IL-10) [14, 33]. In addition, circulating VEGF impedes the maturation and function of dendritic cell (DC) to help tumor escape immune surveillance [34, 35]. On the other hand, hyperactive angiogenesis increases the abundance of pro-tumor lymphocytes. As the consequence of abnormal tumor vessel, tumor hypoxia induces upregulation of chemokine (C-C motif) ligand-22 and chemokine